Disease · MONDO_0026045
Comparisons in its trials45
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 45
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Serlopitant 5 mg vs Placebo: deaths from any cause | 1 of 147 | 0 of 148 | 295 | NCT03677401 | Trial comparisons |
| Serlopitant 5 mg vs Placebo: serious adverse events | 5 of 147 | 2 of 148 | 295 | NCT03677401 | Trial comparisons |
| Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID: deaths from any cause | 0 of 184 | 0 of 103 | 287 | NCT05755438 | Trial comparisons |
| Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID: serious adverse events | 13 of 184 | 5 of 103 | 287 | NCT05755438 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With an Improvement of >=4 From Baseline in Sleep Disturbance Numeric Rating Scale (SD NRS) at Week 16 | 95 of 190 | 11 of 96 | 286 | NCT04501666 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With PP NRS < 2 at Week 4 | 41 of 190 | 1 of 96 | 286 | NCT04501666 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With an Improvement of Greater Than or Equal to (>=) 4 From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16 | 111 of 190 | 16 of 96 | 286 | NCT04501666 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With an Improvement of >= 4 From Baseline in Weekly Average PP NRS at Week 4 | 78 of 190 | 6 of 96 | 286 | NCT04501666 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With an Improvement of >=4 From Baseline in SD NRS at Week 4 | 59 of 190 | 5 of 96 | 286 | NCT04501666 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With PP NRS < 2 at Week 16 | 65 of 190 | 4 of 96 | 286 | NCT04501666 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With an Investigator Global Assessment (IGA) Success at Week 16 | 50 of 190 | 7 of 96 | 286 | NCT04501666 | Trial comparisons |
| Nemolizumab vs Placebo: deaths from any cause | 0 of 187 | 1 of 95 | 282 | NCT04501666 | Trial comparisons |
| Nemolizumab vs Placebo: serious adverse events | 16 of 187 | 10 of 95 | 282 | NCT04501666 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With an Improvement of >=4 From Baseline in Sleep Disturbance Numeric Rating Scale (SD NRS) at Week 16 | 95 of 183 | 19 of 91 | 274 | NCT04501679 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With PP NRS < 2 at Week 4 | 36 of 183 | 2 of 91 | 274 | NCT04501679 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With an Improvement of Greater Than or Equal to (>=) 4 From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16 | 103 of 183 | 19 of 91 | 274 | NCT04501679 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With an Improvement of >= 4 From Baseline in Weekly Average PP NRS at Week 4 | 75 of 183 | 7 of 91 | 274 | NCT04501679 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With an Improvement of >=4 From Baseline in SD NRS at Week 4 | 68 of 183 | 9 of 91 | 274 | NCT04501679 | Trial comparisons |
| Nemolizumab vs Placebo: Number of Participants With PP NRS < 2 at Week 16 | 64 of 183 | 7 of 91 | 274 | NCT04501679 | Trial comparisons |
| Nemolizumab vs Placebo: deaths from any cause | 0 of 183 | 0 of 91 | 274 | NCT04501679 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0026045/comparisons